A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

Ryotaro Nakamura, Corinna La Rosa, Dongyun Yang, Joshua A. Hill, Armin Rashidi, Hannah Choe, Qiao Zhou, Chetan Raj Lingaraju, Teodora Kaltcheva, Jeffrey Longmate, Jennifer Drake, Cynthia Slape, Lupe Duarte, Monzr M. Al Malki, Vinod A. Pullarkat, Ahmed Aribi, Steven Devine, Michael R Verneris, Jeffrey S. Miller, Stephen J. FormanIbrahim Aldoss, Don J. Diamond

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
JournalHaematologica
DOIs
StatePublished - 2024

PubMed: MeSH publication types

  • Journal Article

Cite this